| Study ID | Diagnosis (no. of patients) |
Sub-groups | Survival from Start of Treatment | Progression-free Survival | ||||
|---|---|---|---|---|---|---|---|---|
| Median (months) | 1-year (%) |
HR (95% CI) [p-value] |
Median TTP (months) |
1-year (%) |
HR (95% CI) [p-value] |
|||
| Phase III | ||||||||
| Shepherd, et al., 200033 | NSCLC (204) |
BSC Docetaxel 75 mg/m2 Docetaxel 100 mg/m2 |
4.6 7.5 5.9 |
- - - - - - |
p = 0.010 p = 0.047 |
- - - - - - |
- - - - - - |
- - - - |
| Fossella, et al., 200034 | NSCLC (358) |
Vinorelbine 30 mg/m2 or ifosfamide 2 mg/m2 Docetaxel 75 mg/m2 Docetaxel 100 mg/m2 |
5.4 5.8 6.6 |
10 32 32 |
p = 0.001 p = 0.002 |
7.9 b 8.5 b 8.4 b |
- - - - - - |
p = 0.093 p = 0.046 |
| Hanna, et al., 200432 | NSCLC (571) |
Pemetrexed 500 mg/m2 Docetaxel 75 mg/m2 |
8.3 7.9 |
30 30 |
0.99 | 2.9 2.9 |
- - - - |
0.97 [p = 0.76] |
| Retrospective | ||||||||
| Massarelli, et al., 200335 | NSCLC 43 pts 14 pts |
Various regimens 3rd line 4th line |
5.4 5.9 |
- - - - |
- - - - |
- - - - |
- - - - |
- - |
b Fossella, et al., (2000)34 reported time to progression (TTP) in patients who were censored at the time of administration of subsequent therapy, which is why the TTP is longer than median survival.
Abbreviations: BSC = best supportive care; CI = confidence interval; HR = hazard ratio; no. = number; NR = not reported; NSCLS = non-small cell lung cancer; TTP = time to progression.